Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Soleus sold 474,000 before the end of March

<< Previous

Bullboard Posts

Next >>

Post by SPCEO1on May 18, 2021 3:33pm

220 Views

Post# 33223579

Soleus sold 474,000 before the end of March

They still own nearly 7 million shares as of the end of March but did sell 474,000 between the offering and the end of March. Not sure what, if anything, that might mean but that is what Bloomberg is reporting.

<< Previous

Bullboard Posts

Next >>

The deep connection between mining and First Nations in Canada